xanthan gum

Cefadroxil is a first generation cephalosporin antibiotic intended for oral administration. In the Present investigation, an attempt has been made to increase the therapeutic efficacy to reduce the frequency of administration and to improve the patient compliance by developing the sustained release matrix tablets of Cefadroxil by using direct compression method. Excipients like Xanthun gum, HPMC K 15 M, PVP K 30 are used as matrix polymers. MCC used as diluents, magnesium stearate as lubricant, and talc act as a glidant. The different excipients were tested for their compatibility with the drug Cefadroxil by using FTIR and DSC, which revealed that there was no chemical and physical interaction occurred. Then the Preformulation parameters like bulk density, tapped density, compressibility index, and Hauser’s ratio were analyzed for prepared powder before compression. The thickness of best formulation CF9 is 3.5mm, hardness of best formulation CF9 is 3.6kg/cm2, friability of best formulation CF9 is 0.66%, weight variation of best formulation CF9 is 499±0.39.The In-vitro drug release were performed in the USP Apparatus (basket) using 0.1 N HCL as dissolution media at 50 rpm speed. The sample was done at periodic intervals of 1hr, 2hr, 3hr, 4hr, 5hr, and 6hrs and was replaced with equal volume of dissolution media to maintain the sink condition. The best In-vitro release shown by formula CF9 that is 95% .The results indicate that the selected formulation was stable during the period of accelerated stability studies. The optimized formulation CF9 compared with the marketed sample Cetil-500mg. Marketed sample in-vitro drug release is 98.85%. All evaluated formulations results were found to be satisfied.

A major problem in ocular therapeutics is the attainment of optimal drug concentration at the site of action, which is compromised mainly due to precorneal loss resulting in only a small fraction of the drug being ocularly absorbed. Brimonidine tartrate is an antiglaucomic agent which shows rapid precorneal exclusion and reduced ocular bioavailability when given in form of conventional ophthalmic formulations. The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions may be overcome by the use of in-situ gel forming ophthalmic systems that are instilled as drops into the eye and undergo a sol–gel transition in the cul-de-sac. In the present study, environmentally responsive ophthalmic drug delivery system composed of two gelling polymers with different phase transition mechanisms was developed. Combination of polyacrylic acid (carbopol 934P) and xanthan gum was investigated as ophthalmic vehicle. Different ratios of these polymers were used to prepare environmentally responsive ophthalmic drug delivery system by simple mixing procedure. Developed formulation was assessed for various evaluation parameters such as appearance/clarity, pH, gelation, drug content, rheological measurement, in-vitro release, and sterility testing and stability study. Prepared formulation showed agreeable appearance/clarity, acceptable pH and good gelation property. In-vitro studies demonstrated adequate drug content, desired rheological behaviour and reasonable in-vitro drug release property. Formulation was stable over one month period. In conclusion, the optimum concentration of polymers results in minimized drug loss and sustained drug release. On the basis of these findings, prepared in-situ gel may be considered as a viable alternative to conventional brimonidine tartrate eye drops.